<DOC>
	<DOCNO>NCT00699881</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety cetuximab combine FOLFIRI patient advance gastric cancer fail first-line chemotherapy</brief_summary>
	<brief_title>Study Cetuximab Treat Gastric Cancer</brief_title>
	<detailed_description>Up , although FU base , cisplatin base taxane base regimen , ECF regimen suggest first line therapy A/MGC FDA , standard regimen patient A/MGC second line treatment . Based promising result cetuximab combined FOLFIRI metastatic colorectal cancer , design clinical trial evaluate efficacy safety cetuximab combine FOLFIRI A/MGC patient second line treatment .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm advanced metastatic adenocarcinoma stomach ECOG performance scale ≤ 1 At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Adequate hepatic , renal , heart , hematologic function ( platelets＞80 × 109/L , neutrophil＞2.0 × 109/L , serum creatinine ≤ 1.5mg/dl , total bilirubin within upper limit normal ( ULN ) , serum transaminase≤2.5×the ULN ) Pregnant lactate woman Concurrent cancer History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Neuropathy , brain , leptomeningeal involvement Uncontrolled significant comorbid condition previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Time Progression</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Response rate</keyword>
	<keyword>Quality live</keyword>
</DOC>